Alterity Therapeutics Limited

NASDAQ:ATHE

Biotechnology

Healthcare
$3.12 +9.89%

+$0.53 today

Market cap
$52.77M
Beta
-0.03
P/E (TTM)
-9.9
EPS (TTM)
-$0.07
52W Low $2.66High $7.00

Volume 0.02M

Average 0.05M

ATHE Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Alterity Therapeutics LimitedNASDAQ: ATHE

Weighted Avg Shares · Q2 FY2026 · quarter ended Dec 2025

Weighted avg shares grows 98.7% year over year

Q2 FY2026 weighted avg shares of 16.97M shares rose 98.7% year over year. Over 3 fiscal years it compounded at +38.5% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
16.97M— QoQ
Last fiscal yearJun 2025
10.66M+75.3% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+98.7%——
1 year+75.3%——
3-year CAGR+38.5%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
10.66M AUD
Year-over-year change
+75.3%
4-year CAGR
+39.3%

Weighted Avg Shares vs competitors

How ATHE compares with its peers on the latest reported figures

  • ATHE's FY2025 weighted avg shares of 10.66M shares is the lowest of the 4 companies compared; the peer median is 31.93M shares.
  • Its year-over-year change of +75.3% is the 2nd highest of 4, against a peer median of +27.8%.
  • Over three fiscal years its annual growth of +38.5% compares with a peer median of +36.0%.
ATHE Competitors Peer median
Weighted Avg Shares for ATHE and competitors
Company Period LTM YoY 3-year CAGR
DYAIDyadic International, Inc.LTM Mar 202633.41M +13.2%+4.8%
MAIAMAIA Biotechnology, Inc.LTM Mar 202631.93M +27.8%+51.3%
ANVSAnnovis Bio, Inc.LTM Mar 202622.96M +82.7%+36.0%
ATHEAlterity Therapeutics LimitedFY202510.66M +75.3%+38.5%
Peer median (excluding ATHE) 31.93M+27.8%+36.0%

Competitors are the stored peer set for ATHE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

AUD
Metric
FY2021
Jun 2021
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
Revenue4.34M5.12M3.92M4.02M5.44M
Cost of Revenue360.03K364.67K285.07K214.3K127.52K
Gross Profit3.98M4.76M3.63M3.8M5.31M
Gross Margin91.7%92.9%92.7%94.7%97.7%
Research & Development12.28M14.75M13.2M18.64M14.4M
Selling, General & Admin6.87M5.51M5.04M4.76M5.48M
Operating Expenses19.16M20.26M18.24M23.41M19.89M
Depreciation & Amortization18.66K54.21K37.85K35.34K28.31K
EBITDA(15.16M)(17.39M)(14.6M)(19.57M)(14.63M)
EBITDA Margin-349.3%-339.5%-372.8%-486.9%-269.0%
Operating Income(15.18M)(15.5M)(14.64M)(19.6M)(14.57M)
Operating Margin-349.8%-302.6%-373.7%-487.7%-268.0%
Interest Income20.68K2.5K16.44K268.42K446.29K
Interest Expense00000
Other Income / Expenses(133.04K)2.72M904.68K524.33K2.49M
Income Before Tax(15.31M)(12.78M)(13.7M)(19.08M)(12.08M)
Pre-Tax Margin-352.8%-249.4%-349.9%-474.6%-222.1%
Income Tax Expense(3.08M)70.01K104.46K46.09K68.06K
Net Income(15.31M)(12.85M)(13.81M)(19.12M)(12.15M)
Net Margin-352.8%-250.7%-352.5%-475.8%-223.4%
EPS (Basic)(5.40)(3.18)(3.42)(3.12)(1.14)
EPS (Diluted)(5.40)(3.18)(3.42)(3.12)(1.14)
Weighted Avg Shares2.83M4.01M4.05M6.08M10.66M
Weighted Avg Shares (Diluted)2.83M4.01M4.05M6.08M10.66M

Alterity Therapeutics Limited

NASDAQ:ATHE

Intrinsic Alpha fair value

Locked

Current Price

$3.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.